Hangyuan Guo
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hangyuan Guo has a total of 96 co-authors. Here are the top co-authors by number of shared publications:
Jong-Dae Lee
12 shared publicationsYangbo Xing
Shaoxing People's Hospital
11 shared publicationsHui Lin
Zhejiang University, Hangzhou, Zhejiang, China
10 shared publicationsJufang Chi
Shaoxing People's Hospital
10 shared publicationsFang Peng
Department of Cardiology, Shaoxing People's Hospital, Zhejiang University School of Medicine, Shaoxing, China
9 shared publicationsLiping Meng
Shaoxing People's Hospital
9 shared publications
Latest Publications
- Open Access
- 29 November 2022
- Published by Springer Nature in Research Square
Role of Yellow Wine in Homocysteine-induced Endothelial Progenitor Cell Function
Background Increased Hcy level is an independent risk factor for coronary heart disease (CHD). It was proposed that yellow rice wine improves Hcy-induced EPCs dysfunction and inhibits the development of atherosclerotic plaques. In this study, we observed whether yellow rice wine and red wine improve the properties of homocysteine (Hcy)-induced endothelial progenitor cells (EPCs). Methods The bone marrow of rats was extracted to isolate EPCs from the bone marrow cell suspension using density-gradient centrifugation. The cells were inoculated on culture plates coated with human fibronectin (HFN), to induce mononuclear cell differentiation into EPCs. Samples were divided into 5 groups including a control group. Western blotting. and NO assays were used respectively to observe the generation of eNOS, p-eNOS and NO. MTT and transwell assays were conducted. Apoptosis and in vitro angiogenesis of EPCs were determined. Results Compared with the control group, the potential for proliferation, migration and in vitro angiogenesis of EPCs decreased significantly following Hcy intervention (P < 0.01).The production of eNOS, NO and p-eNOS was significantly reduced (P < 0.01). Intervention with yellow rice wine and red wine significantly improved the effect of Hcy in EPCs (P < 0.01). Further, comparison with the control group indicated that the intervention also significantly improved the proliferation, migration and angiogenesis of EPCs in vitro (P < 0.05). Compared with the Hcy group, the alcohol group did not show significant functional changes in EPCs (P > 0.05). No impact on apoptotic function of EPCs was observed (P > 0.05). Hcy significantly lowers the capacity of proliferation, migration and in vitro angiogenesis of EPCs and reduces the production of eNOS, p-eNOS and NO. Conclusion Our results showed Hcy significantly lowers the capacity of proliferation, migration and in vitro angiogenesis of EPCs and reduces the production of eNOS, p-eNOS and NO,which indicates that yellow rice wine and red wine in small doses improve the functions of EPCs.
- 29 November 2022
- Published by Springer Nature in Research Square
Open AccessRole of Yellow Wine in Homocysteine-induced Endothelial Progenitor Cell Function
Background Increased Hcy level is an independent risk factor for coronary heart disease (CHD). It was proposed that yellow rice wine improves Hcy-induced EPCs dysfunction and inhibits the development of atherosclerotic plaques. In this study, we observed whether yellow rice wine and red wine improve the properties of homocysteine (Hcy)-induced endothelial progenitor cells (EPCs). Methods The bone marrow of rats was extracted to isolate EPCs from the bone marrow cell suspension using density-gradient centrifugation. The cells were inoculated on culture plates coated with human fibronectin (HFN), to induce mononuclear cell differentiation into EPCs. Samples were divided into 5 groups including a control group. Western blotting. and NO assays were used respectively to observe the generation of eNOS, p-eNOS and NO. MTT and transwell assays were conducted. Apoptosis and in vitro angiogenesis of EPCs were determined. Results Compared with the control group, the potential for proliferation, migration and in vitro angiogenesis of EPCs decreased significantly following Hcy intervention (P < 0.01).The production of eNOS, NO and p-eNOS was significantly reduced (P < 0.01). Intervention with yellow rice wine and red wine significantly improved the effect of Hcy in EPCs (P < 0.01). Further, comparison with the control group indicated that the intervention also significantly improved the proliferation, migration and angiogenesis of EPCs in vitro (P < 0.05). Compared with the Hcy group, the alcohol group did not show significant functional changes in EPCs (P > 0.05). No impact on apoptotic function of EPCs was observed (P > 0.05). Hcy significantly lowers the capacity of proliferation, migration and in vitro angiogenesis of EPCs and reduces the production of eNOS, p-eNOS and NO. Conclusion Our results showed Hcy significantly lowers the capacity of proliferation, migration and in vitro angiogenesis of EPCs and reduces the production of eNOS, p-eNOS and NO,which indicates that yellow rice wine and red wine in small doses improve the functions of EPCs.
- 24 March 2020
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 34 (3) , 291-301
Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy
Purpose The pro-aging miRNA, miR-34a, is hyperactivated in the cardiac myocardial tissues of patients and mice with diabetes, leading to diabetic cardiomyopathy (DCM). Increasing evidence suggests that dihydromyricetin (DHM) can be used to effectively treat cardiomyopathy. In this study, we investigated whether DHM affects the expression of miR-34a in DCM. Methods The expression of miR-34a in high-glucose-induced cardiomyocytes and in the heart tissue of diabetic mice was determined by microRNA isolation and quantitative reverse transcription-polymerase chain reaction. Lipofectamine 3000 was used to transfect cardiomyocytes with miR-34a inhibitor, miR-34a mimics, and miR-control. These agents were intravenously injected into the tail vein of streptozotocin-induced diabetic mice. Autophagy and apoptosis were assessed in high-glucose-induced cardiomyocytes and cardiac tissue in diabetic mice by western blotting, immunofluorescence, Masson staining, hematoxylin and eosin staining (H&E), and electron microscopy. Results DHM clearly ameliorated the cardiac dysfunction in the diabetic mice. The expression of miR-34a was up-regulated in high-glucose-induced cardiomyocytes and in the hearts of diabetic mice, thus impairing autophagy. Treatment with DHM decreased the expression of miR-34a and rescued the impairment of autophagy in high-glucose-induced cardiomyocytes and in the heart tissue of diabetic mice, while the miR-34a mimic offset the effect of DHM with respect to the development of DCM by inhibiting autophagy. Conclusions By decreasing the expression of miR-34a, DHM restores impaired autophagy, and thus ameliorates DCM. Therefore, DHM may potentially be used in the treatment of DCM.
- 24 March 2020
- Published by Springer Nature in Cardiovascular Drugs and Therapy
- Vol. 34 (3) , 291-301
Dihydromyricetin Prevents Diabetic Cardiomyopathy via miR-34a Suppression by Activating Autophagy
Purpose The pro-aging miRNA, miR-34a, is hyperactivated in the cardiac myocardial tissues of patients and mice with diabetes, leading to diabetic cardiomyopathy (DCM). Increasing evidence suggests that dihydromyricetin (DHM) can be used to effectively treat cardiomyopathy. In this study, we investigated whether DHM affects the expression of miR-34a in DCM. Methods The expression of miR-34a in high-glucose-induced cardiomyocytes and in the heart tissue of diabetic mice was determined by microRNA isolation and quantitative reverse transcription-polymerase chain reaction. Lipofectamine 3000 was used to transfect cardiomyocytes with miR-34a inhibitor, miR-34a mimics, and miR-control. These agents were intravenously injected into the tail vein of streptozotocin-induced diabetic mice. Autophagy and apoptosis were assessed in high-glucose-induced cardiomyocytes and cardiac tissue in diabetic mice by western blotting, immunofluorescence, Masson staining, hematoxylin and eosin staining (H&E), and electron microscopy. Results DHM clearly ameliorated the cardiac dysfunction in the diabetic mice. The expression of miR-34a was up-regulated in high-glucose-induced cardiomyocytes and in the hearts of diabetic mice, thus impairing autophagy. Treatment with DHM decreased the expression of miR-34a and rescued the impairment of autophagy in high-glucose-induced cardiomyocytes and in the heart tissue of diabetic mice, while the miR-34a mimic offset the effect of DHM with respect to the development of DCM by inhibiting autophagy. Conclusions By decreasing the expression of miR-34a, DHM restores impaired autophagy, and thus ameliorates DCM. Therefore, DHM may potentially be used in the treatment of DCM.
- Open Access
- 21 June 2019
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (9) , 6034-6047
Yellow Wine Polyphenolic Compounds prevents Doxorubicin‐induced cardiotoxicity through activation of the Nrf2 signalling pathway
Doxorubicin (DOX) is considered as the major culprit in chemotherapy‐induced cardiotoxicity. Yellow wine polyphenolic compounds (YWPC), which are full of polyphenols, have beneficial effects on cardiovascular disease. However, their role in DOX‐induced cardiotoxicity is poorly understood. Due to their antioxidant property, we have been suggested that YWPC could prevent DOX‐induced cardiotoxicity. In this study, we found that YWPC treatment (30 mg/kg/day) significantly improved DOX‐induced cardiac hypertrophy and cardiac dysfunction. YWPC alleviated DOX‐induced increase in oxidative stress levels, reduction in endogenous antioxidant enzyme activities and inflammatory response. Besides, administration of YWPC could prevent DOX‐induced mitochondria‐mediated cardiac apoptosis. Mechanistically, we found that YWPC attenuated DOX‐induced reactive oxygen species (ROS) and down‐regulation of transforming growth factor beta 1 (TGF‐β1)/smad3 pathway by promoting nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) nucleus translocation in cultured H9C2 cardiomyocytes. Additionally, YWPC against DOX‐induced TGF‐β1 up‐regulation were abolished by Nrf2 knockdown. Further studies revealed that YWPC could inhibit DOX‐induced cardiac fibrosis through inhibiting TGF‐β/smad3‐mediated ECM synthesis. Collectively, our results revealed that YWPC might be effective in mitigating DOX‐induced cardiotoxicity by Nrf2‐dependent down‐regulation of the TGF‐β/smad3 pathway.
- 21 June 2019
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 23 (9) , 6034-6047
Open AccessYellow Wine Polyphenolic Compounds prevents Doxorubicin‐induced cardiotoxicity through activation of the Nrf2 signalling pathway
Doxorubicin (DOX) is considered as the major culprit in chemotherapy‐induced cardiotoxicity. Yellow wine polyphenolic compounds (YWPC), which are full of polyphenols, have beneficial effects on cardiovascular disease. However, their role in DOX‐induced cardiotoxicity is poorly understood. Due to their antioxidant property, we have been suggested that YWPC could prevent DOX‐induced cardiotoxicity. In this study, we found that YWPC treatment (30 mg/kg/day) significantly improved DOX‐induced cardiac hypertrophy and cardiac dysfunction. YWPC alleviated DOX‐induced increase in oxidative stress levels, reduction in endogenous antioxidant enzyme activities and inflammatory response. Besides, administration of YWPC could prevent DOX‐induced mitochondria‐mediated cardiac apoptosis. Mechanistically, we found that YWPC attenuated DOX‐induced reactive oxygen species (ROS) and down‐regulation of transforming growth factor beta 1 (TGF‐β1)/smad3 pathway by promoting nuclear factor (erythroid‐derived 2)‐like 2 (Nrf2) nucleus translocation in cultured H9C2 cardiomyocytes. Additionally, YWPC against DOX‐induced TGF‐β1 up‐regulation were abolished by Nrf2 knockdown. Further studies revealed that YWPC could inhibit DOX‐induced cardiac fibrosis through inhibiting TGF‐β/smad3‐mediated ECM synthesis. Collectively, our results revealed that YWPC might be effective in mitigating DOX‐induced cardiotoxicity by Nrf2‐dependent down‐regulation of the TGF‐β/smad3 pathway.
- 1 June 2019
- Vol. 39 (3) , 418-424
Effect of Jiawei Shenfu decoction on tumor necrosis factor-alpha and nuclear factor-kappa B in patients who have chronic heart failure with syndromes of deficiency of heart Yang
OBJECTIVE: To examine the clinical efficacy of Jiawei Shenfu decoction on tumor necrosis factor-alpha (TNF-alpha) and nuclear factor-kappa B (NF-kappa B) levels in patients who have chronic heart failure with syndromes of deficiency of heart Yang. METHODS: A total of 63 patients with syndromes of deficiency of heart Yang (chronic heart failure) were enrolled. Patients were randomly divided into the control group and Jiawei Shenfu group. All patients received standard medications for treatment of chronic heart failure. Patients in the Jiawei Shenfu group were additionally provided Jiawei Shenfu decoction one dose daily. Treatments continued for 4 consecutive weeks. The primary endpoint was the change in plasma B-type natriuretic peptide (BNP), NF-kappa B, and TNF-alpha levels during 4 weeks of treatment. RESULTS: At the 4-week follow-up, a significant reduction in BNP levels compared with baseline was observed in both groups, but the Jiawei Shenfu decoction group showed a significantly greater reduction than did the control group. The Jiawei Shenfu group also showed superior performance regarding the Minnesota Living with Heart Failure Questionnaire score, the Chinese medicine syndrome score, heart rate, left ventricular ejection fraction, and 6-min walking distance compared with the control group. The degree of changes in NF-kappa B and TNF-alpha levels in the Jiawei Shenfu group was more significant than that in the control group. CONCLUSION: Routine medicine combined with Jiawei Shenfu decoction for patients with heart Yang deficiency syndrome in chronic heart failure can improve the left ventricular ejection fraction and cardiac function, and reduce BNP levels. The mechanism may be related to inhibition of pro-inflammatory cytokines and the NF-kappa B-induced kinase pathway, leading to amelioration of the inflammatory response. (C) 2019 JTCM. All rights reserved.
- 1 June 2019
- Vol. 39 (3) , 418-424
Effect of Jiawei Shenfu decoction on tumor necrosis factor-alpha and nuclear factor-kappa B in patients who have chronic heart failure with syndromes of deficiency of heart Yang
OBJECTIVE: To examine the clinical efficacy of Jiawei Shenfu decoction on tumor necrosis factor-alpha (TNF-alpha) and nuclear factor-kappa B (NF-kappa B) levels in patients who have chronic heart failure with syndromes of deficiency of heart Yang. METHODS: A total of 63 patients with syndromes of deficiency of heart Yang (chronic heart failure) were enrolled. Patients were randomly divided into the control group and Jiawei Shenfu group. All patients received standard medications for treatment of chronic heart failure. Patients in the Jiawei Shenfu group were additionally provided Jiawei Shenfu decoction one dose daily. Treatments continued for 4 consecutive weeks. The primary endpoint was the change in plasma B-type natriuretic peptide (BNP), NF-kappa B, and TNF-alpha levels during 4 weeks of treatment. RESULTS: At the 4-week follow-up, a significant reduction in BNP levels compared with baseline was observed in both groups, but the Jiawei Shenfu decoction group showed a significantly greater reduction than did the control group. The Jiawei Shenfu group also showed superior performance regarding the Minnesota Living with Heart Failure Questionnaire score, the Chinese medicine syndrome score, heart rate, left ventricular ejection fraction, and 6-min walking distance compared with the control group. The degree of changes in NF-kappa B and TNF-alpha levels in the Jiawei Shenfu group was more significant than that in the control group. CONCLUSION: Routine medicine combined with Jiawei Shenfu decoction for patients with heart Yang deficiency syndrome in chronic heart failure can improve the left ventricular ejection fraction and cardiac function, and reduce BNP levels. The mechanism may be related to inhibition of pro-inflammatory cytokines and the NF-kappa B-induced kinase pathway, leading to amelioration of the inflammatory response. (C) 2019 JTCM. All rights reserved.
- 26 April 2019
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 50 (4) , 305-314
Impaired autophagy mediates hyperhomocysteinemia-induced HA-VSMC phenotypic switching
Hyperhomocysteinemia (HHcy) is a highly-related risk factor in vascular smooth muscle cell (VSMC) phenotypic modulation and atherosclerosis. Growing evidence indicated that autophagy is involved in pathological arterial changes. However, the risk mechanisms by which homocysteine and VSMC autophagy interact with cardiovascular disease are poorly understood. This study verified the homocysteine-responsive endoplasmic reticulum protein promotion of VSMC phenotypic switching, and the formation of atherosclerotic plaque in vitro. We found that impaired autophagy, as evidenced by decreased levels of MAP1LC3B II/MAP1LC3B I, has a vital role in HHcy-induced human aortic (HA)-VSMC phenotypic switching, with a decrease in contractile proteins (SM α-actin and calponin) and an increase in osteopontin. Knockdown of the essential autophagy gene Atg7 by small interfering RNA promoted HA-VSMC phenotypic switching, indicating that impaired autophagy induces phenotypic switching in these cells. HHcy co-treatment with rapamycin triggered autophagy, which alleviated HA-VSMC phenotypic switching. Finally, we found that Krüppel-like factor 4 (KLF4), a zinc-finger transcription factor for maintaining genomic stability by resisting oxidative stress and restoring autophagy, is closely involved in this process. HHcy clearly decreased KLF4 expression. KLF4-specific siRNA aggravated defective autophagy and phenotypic switching. Mechanistically, KLF4 regulated the HHcy-induced decrease in HA-VSMC autophagy via the m-TOR signaling pathway. In conclusion, these results demonstrated that the KLF4-dependent rapamycin signaling pathway is a novel mechanism underlying HA-VSMC phenotypic switching and is crucial for HHcy-induced HA-VSMCs with defective autophagy to accelerate early atherosclerosis.
- 26 April 2019
- Published by Springer Nature in Journal of Molecular Histology
- Vol. 50 (4) , 305-314
Impaired autophagy mediates hyperhomocysteinemia-induced HA-VSMC phenotypic switching
Hyperhomocysteinemia (HHcy) is a highly-related risk factor in vascular smooth muscle cell (VSMC) phenotypic modulation and atherosclerosis. Growing evidence indicated that autophagy is involved in pathological arterial changes. However, the risk mechanisms by which homocysteine and VSMC autophagy interact with cardiovascular disease are poorly understood. This study verified the homocysteine-responsive endoplasmic reticulum protein promotion of VSMC phenotypic switching, and the formation of atherosclerotic plaque in vitro. We found that impaired autophagy, as evidenced by decreased levels of MAP1LC3B II/MAP1LC3B I, has a vital role in HHcy-induced human aortic (HA)-VSMC phenotypic switching, with a decrease in contractile proteins (SM α-actin and calponin) and an increase in osteopontin. Knockdown of the essential autophagy gene Atg7 by small interfering RNA promoted HA-VSMC phenotypic switching, indicating that impaired autophagy induces phenotypic switching in these cells. HHcy co-treatment with rapamycin triggered autophagy, which alleviated HA-VSMC phenotypic switching. Finally, we found that Krüppel-like factor 4 (KLF4), a zinc-finger transcription factor for maintaining genomic stability by resisting oxidative stress and restoring autophagy, is closely involved in this process. HHcy clearly decreased KLF4 expression. KLF4-specific siRNA aggravated defective autophagy and phenotypic switching. Mechanistically, KLF4 regulated the HHcy-induced decrease in HA-VSMC autophagy via the m-TOR signaling pathway. In conclusion, these results demonstrated that the KLF4-dependent rapamycin signaling pathway is a novel mechanism underlying HA-VSMC phenotypic switching and is crucial for HHcy-induced HA-VSMCs with defective autophagy to accelerate early atherosclerosis.
- 14 February 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (5) , 717-726
A left common pulmonary vein: Anatomical variant predicting good outcomes of repeat catheter ablation for atrial fibrillation
Introduction: A left common pulmonary vein (LCPV) is a common anatomical variant in atrial fibrillation (AF) patients. Whether an LCPV influences outcomes of repeated radiofrequency catheter ablation (RFCA) for AF has not been elucidated.Methods: From a prospectively collected database, we enrolled 154 patients who received repeated RFCA for recurrent AF after the initial RFCA (56 ± 9 years, 72% paroxysmal AF, 32 patients with an LCPV, and 122 patients with typical left‐sided pulmonary veins [PVs]). Median postprocedural follow‐up was 26 months. The primary outcome was an episode of AF, atrial tachyarrhythmia, or atrial flutter lasting for more than 30 seconds, after the 3 months blanking period following the repeated procedure.Results: After the follow‐up period, 75 patients suffered recurrence after repeated ablation. In the Kaplan‐Meier analysis, an LCPV was significantly associated with less recurrence (hazard ratio [HR]: 0.39; 95% confidence interval [CI]: 0.28‐0.79; P = 0.005). In subgroup analysis, the significant association persisted in paroxysmal AF patients. Regarding persistent AF patients, an LCPV tended to be associated with less recurrence with no statistical significance (HR: 0.40; 95% CI: 0.20‐1.03; P = 0.067). In multivariate analyses, an LCPV still independently predicted freedom from recurrence (HR: 0.44; 95% CI: 0.22‐0.88; P = 0.02).Conclusion: Compared with typical left‐sided PVs, an LCPV was independently associated with better outcomes after repeated RFCA of AF, particularly in patients with paroxysmal AF.
- 14 February 2019
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (5) , 717-726
A left common pulmonary vein: Anatomical variant predicting good outcomes of repeat catheter ablation for atrial fibrillation
Introduction: A left common pulmonary vein (LCPV) is a common anatomical variant in atrial fibrillation (AF) patients. Whether an LCPV influences outcomes of repeated radiofrequency catheter ablation (RFCA) for AF has not been elucidated.Methods: From a prospectively collected database, we enrolled 154 patients who received repeated RFCA for recurrent AF after the initial RFCA (56 ± 9 years, 72% paroxysmal AF, 32 patients with an LCPV, and 122 patients with typical left‐sided pulmonary veins [PVs]). Median postprocedural follow‐up was 26 months. The primary outcome was an episode of AF, atrial tachyarrhythmia, or atrial flutter lasting for more than 30 seconds, after the 3 months blanking period following the repeated procedure.Results: After the follow‐up period, 75 patients suffered recurrence after repeated ablation. In the Kaplan‐Meier analysis, an LCPV was significantly associated with less recurrence (hazard ratio [HR]: 0.39; 95% confidence interval [CI]: 0.28‐0.79; P = 0.005). In subgroup analysis, the significant association persisted in paroxysmal AF patients. Regarding persistent AF patients, an LCPV tended to be associated with less recurrence with no statistical significance (HR: 0.40; 95% CI: 0.20‐1.03; P = 0.067). In multivariate analyses, an LCPV still independently predicted freedom from recurrence (HR: 0.44; 95% CI: 0.22‐0.88; P = 0.02).Conclusion: Compared with typical left‐sided PVs, an LCPV was independently associated with better outcomes after repeated RFCA of AF, particularly in patients with paroxysmal AF.
- 1 October 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 268, 120-124
Transformation from persistent atrial fibrillation to paroxysmal type after initial ablation predicts success of repeated ablation
- 1 October 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 268, 120-124
Transformation from persistent atrial fibrillation to paroxysmal type after initial ablation predicts success of repeated ablation
- 1 October 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 269, 242-249
Knockdown of Herp alleviates hyperhomocysteinemia mediated atherosclerosis through the inhibition of vascular smooth muscle cell phenotype switching
- 1 October 2018
- Published by Elsevier in International Journal of Cardiology
- Vol. 269, 242-249
Knockdown of Herp alleviates hyperhomocysteinemia mediated atherosclerosis through the inhibition of vascular smooth muscle cell phenotype switching